(650) 766-1883
Email Us
The EpicOncology™ platform provides detailed epidemiology data for the world’s leading cancer research & development. You’ll find comprehensive cancer data sets for 42 countries in the current data release.
Current and forecasted statistics, flow diagrams, and every data source logged and globally consistent…no other commercially available dataset offers the depth of coverage available in EpicOncology™.
| NORTH AMERICA | CENTRAL AMERICA | SOUTH AMERICA | ASIA | EUROPE | MIDDLE EAST |
| United States | Costa Rica | Argentina | Japan | EU5 (DE, ES, FR, IT, UK) | Egypt |
| Canada | Dominican Republic | Brazil | China Mainland | France | Israel |
| Mexico | Chile | China Mainland Rural | Germany | Saudi Arabia | |
| Panama | Columbia | China Mainland Urban | Italy | Turkey | |
| Puerto Rico | Ecuador | China SAR* | Spain | ||
| Peru | Australia | United Kingdom | |||
| South Korea | Austria | ||||
| Taiwan | Belgium | ||||
| India | Denmark | ||||
| Malaysia | Finland | ||||
| Singapore | Netherlands | ||||
| Thailand | Norway | ||||
| Poland | |||||
| Portugal | |||||
| Russia | |||||
| Sweden | |||||
| Switzerland |
*Special Administrative Regions (Hong Kong and Macao)
EpicOncology™ includes detailed cancer data for more than 55 cancer sites and 110+ subtypes and biomarkers. Every cancer site, subtype, and biomarker listed below, you’ll find in EpicOncology‘s data sets.
| Cancers | Subsets | Biomarkers |
| All Sites1 | — | — |
| Biliary Tract | Gallbladder Intrahepatic Bile Duct Extrahepatic Bile Duct Ampullary Other Histologies |
NTRK1 Gene Fusions |
| Bladder | — | MSI-High MSI-Stable |
| Other Urinary | Renal Pelvis Ureter Other Histologies |
MSI-High MSI-Stable |
| Bone | Osteosarcoma Chondrosarcoma Ewing’s Sarcoma Other Histologies |
NTRK1 Gene Fusions |
| Brain | WHO Grade I WHO Grade II WHO Grade III (Anaplastic) WHO Grade IV (Glioblastoma) Secondary Glioblastoma |
IDH1 Mutations MSI-High MSI-Stable NTRK2 Gene Fusion |
| Breast | HR-Positive, HER2-Positive HR-Positive, HER2-Negative HR-Negative, HER2-Positive HR-Negative, HER2-Negative (TNBC) |
PBRCA1 Positive BRCA2 Positive HER2 Positive Hormone Positive MSI-High MSI-Stable |
| Cervical | — | — |
| Colorectal (Total) | Colon Rectal |
Other BRAF Mutations KRAS Mutation KRAS Wild-Type MSI-High MSI-Stable NRAS Mutation |
| Esophageal | Adenocarcinoma (Non-GEJ) Adenocarcinoma (GE Junction) Squamous Cell Other Histologies |
MSI-High MSI-Stable |
| Gastric | Adenocarcinoma (Non-GEJ) Adenocarcinoma (GE Junction) |
HER2 Positive MSI-High MSI-Stable |
| Gastrointestinal Stromal Tumors (GIST) |
Gastric Small Intestine Other Sites |
— |
| Head and Neck (Total) | Squamous Cell Non-Squamous Cell |
— |
| Laryngeal Oral Cavity Oropharyngeal Nasopharyngeal Hypopharyngeal Nasal Cavity & Sinuses |
Squamous Cell Non-Squamous Cell |
— |
| Liver: AJCC Staging BCLC Staging Child-Pugh Classification |
Hepatocellular Other Histologies |
— |
| Lung, Non-Small Cell (NSCLC) | Adenocarcinoma Squamous Cell Large Cell Other Histologies |
ALK Mutation EGFR Mutation KRAS Mutation MSI-High MSI-Stable NTRK1 Gene Fusions |
| Lung, Small Cell (SCLC) | Limited Extensive |
MSI-High MSI-Stable NTRK1 Gene Fusions |
| Melanoma | — | BRAF V600E Mutation Other BRAF Mutations MSI-High MSI-Stable NRAS Mutation |
| Mesothelioma | — | MSI-High MSI-Stable |
| Ovarian | High-Grade Serous Low-Grade Serous Other Histologies |
BRCA1 Mutations BRCA2 Mutations Non-BRCA HRD Mutations MSI-High MSI Stable |
| Fallopian Tube | High-Grade Serous Low-Grade Serous Other Histologies |
BRCA1 Mutations BRCA2 Mutations Non-BRCA HRD Mutations |
| Pancreatic | Adenocarcinoma PNET Other Histologies |
MSI-High MSI-Stable |
| Prostate | Hormone Sensitive Castrate Resistant |
BRCA1 Mutations BRCA2 Mutations MSI-High MSI-Stable |
| Renal Cell (Kidney) | Clear Cell Non-Clear Cell |
MSI-High MSI-Stable |
| Sarcoma, Soft Tissue | Fibrohistiocytoma Liposarcoma Leiomyosarcoma Rhabdomyosarcoma Other Histologies |
MSI-High MSI-Stable |
| Thyroid | Follicular Papillary Medullary Anaplastic Other Histologies |
MSI-High MSI-Stable |
| Endometrial | Endometroid Sarcoma Other Histologies |
MSI-High MSI-Stable |
| Other Uterine | Endometroid Sarcoma Other Histologies |
MSI-High MSI-Stable |
1. All sites: includes some cancers that are NOT covered in EpicOncology™ (e.g., small intestine) but excludes non-melanoma skin cancers.
| Cancers | Subsets | Biomarkers |
| Leukemia: Acute Lymphocytic Leukemia (ALL) | Ph-Positive Ph-Negative |
— |
| Leukemia: Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML) Acute Promyelocytic Leukemia (APL) Secondary AML (prior MDS-IPSS-R Very Low) Secondary AML (prior MDS-IPSS-R Low) Secondary AML (prior MDS-IPSS-R Intermediate) Secondary AML (prior MDS-IPSS-R High) Secondary AML (prior MDS-IPSS-R Very High) Secondary AML (prior MPN) |
CEBPA Mutation IDH1 Mutations FLT3-ITD Only NPM1 & FLT3-ITD NPM1 Mutation Only MSI-Stable |
| Leukemia: Chronic Lymphocytic Leukemia (CLL) | — | — |
| Leukemia: Chronic Myelogenous Leukemia (CML) | Chronic Phase Accelerated Phase Blast Crisis |
— |
| Lymphoma, Hodgkin | — | — |
| Lymphoma, Non-Hodgkin (NHL) | Follicular (Grade 1-2) Lymphoma Follicular (Grade 3A) Lymphoma Other Indolent B-cell Lymphoma Follicular (Grade 3B) Lymphoma Mantle Cell Lymphoma Diffuse, Large B-Cell Lymphoma (DLBCL) Other Aggressive B-cell Lymphoma Cutaneous T-cell Lymphoma (CTCL) Other Indolent T-cell Lymphoma Peripheral T-cell Lymphoma (PTCL) Other Aggressive T-cell Lymphoma |
— |
| Multiple Myeloma | Transplant Eligible Transplant Ineligible |
— |
| Myelodysplastic Syndromes (MDS) | WHO Subsets IPSS-R |
— |
| Myeloproliferative Neoplasms (MPN) | Polycythemia vera (PCV) Essential Thrombocytosis (ET) Myelofibrosis (MF) |
JAK2 |
How does EpicOncology™ present all this data to you? Through an ‘Epic’ analytics platform that helps you query, map out, and analyze it.